Menu
Solution
Turnkey Multidisciplinary Cancer (MDC) Care Solution
Advanced Tumor Board/MDT Management
Network and Referral Expansion
Patient Tracking, Quality and Accreditation
Patient Loyalty and Survivorship Planning
Cancer Data Access and Insights
Resources
All Resources
Blog
Case Studies
Education
CME
News
About
About Us
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
Solution
Turnkey Multidisciplinary Cancer (MDC) Care Solution
Advanced Tumor Board/MDT Management
Network and Referral Expansion
Patient Tracking, Quality and Accreditation
Patient Loyalty and Survivorship Planning
Cancer Data Access and Insights
Resources
All Resources
Blog
Case Studies
Education
CME
News
About
About Us
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
SCHEDULE A DEMO
Home
Resources
Education
Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result
Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result
Date Recorded:
March 1, 2021
Recording Length:
20 min
Topics:
EGFR
,
Exon 19 Deletion
,
Lung Cancer
Latest
Jan 19, 2023 | Blog
OncoLens Empowers Molecular Tumor Boards
Read more
Dec 13, 2022 | Blog
OncoLens Streamlines NAPRC Accreditation through Advanced Patient Tracking and Analytics Reporting
Read more
Dec 6, 2022 | News
ACCC and Boston University Present the Project ECHO® Eight-Part Webinar Series, Powered by OncoLens
Read more
Sep 22, 2022 | News
Women-Led Digital Health: The Women Behind Digital Health Innovations and the Journey to Success
Read more
